vs

Side-by-side financial comparison of Absci Corp (ABSI) and Dianthus Therapeutics, Inc. (DNTH). Click either name above to swap in a different company.

Absci Corp is the larger business by last-quarter revenue ($650.0K vs $284.0K, roughly 2.3× Dianthus Therapeutics, Inc.). Absci Corp runs the higher net margin — -4548.0% vs -22687.3%, a 18139.3% gap on every dollar of revenue. On growth, Absci Corp posted the faster year-over-year revenue change (-2.3% vs -78.6%). Absci Corp produced more free cash flow last quarter ($-29.3M vs $-47.1M). Over the past eight quarters, Absci Corp's revenue compounded faster (-6.5% CAGR vs -44.6%).

Absci Corp is a synthetic biology and AI-powered biotech firm focused on advancing next-generation biologic drug discovery and development. It delivers integrated protein engineering solutions to pharmaceutical and biopharmaceutical partners, enabling faster creation of novel antibodies, therapeutic proteins and other complex biologic candidates to address unmet global medical needs.

Dianthus Therapeutics is a clinical-stage biopharmaceutical firm focused on developing targeted therapies for rare immunological and inflammatory diseases. It advances antibody-based candidates to address unmet needs of severe patients, operating primarily in the U.S. with global development partners.

ABSI vs DNTH — Head-to-Head

Bigger by revenue
ABSI
ABSI
2.3× larger
ABSI
$650.0K
$284.0K
DNTH
Growing faster (revenue YoY)
ABSI
ABSI
+76.3% gap
ABSI
-2.3%
-78.6%
DNTH
Higher net margin
ABSI
ABSI
18139.3% more per $
ABSI
-4548.0%
-22687.3%
DNTH
More free cash flow
ABSI
ABSI
$17.8M more FCF
ABSI
$-29.3M
$-47.1M
DNTH
Faster 2-yr revenue CAGR
ABSI
ABSI
Annualised
ABSI
-6.5%
-44.6%
DNTH

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ABSI
ABSI
DNTH
DNTH
Revenue
$650.0K
$284.0K
Net Profit
$-29.6M
$-64.4M
Gross Margin
Operating Margin
-4775.5%
-24486.3%
Net Margin
-4548.0%
-22687.3%
Revenue YoY
-2.3%
-78.6%
Net Profit YoY
-2.0%
-126.6%
EPS (diluted)
$-0.19
$-1.53

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABSI
ABSI
DNTH
DNTH
Q4 25
$650.0K
$284.0K
Q3 25
$396.0K
Q2 25
$593.0K
Q1 25
$1.2M
$1.2M
Q4 24
$665.0K
$1.3M
Q3 24
$1.7M
$2.2M
Q2 24
$1.3M
$1.9M
Q1 24
$898.0K
$874.0K
Net Profit
ABSI
ABSI
DNTH
DNTH
Q4 25
$-29.6M
$-64.4M
Q3 25
$-36.8M
Q2 25
$-30.6M
Q1 25
$-26.3M
$-29.5M
Q4 24
$-29.0M
$-28.4M
Q3 24
$-27.4M
$-25.2M
Q2 24
$-24.8M
$-17.6M
Q1 24
$-22.0M
$-13.7M
Operating Margin
ABSI
ABSI
DNTH
DNTH
Q4 25
-4775.5%
-24486.3%
Q3 25
-10173.7%
Q2 25
-5293.9%
Q1 25
-2351.9%
-2852.7%
Q4 24
-4477.3%
-2406.9%
Q3 24
-1698.7%
-1376.6%
Q2 24
-2104.0%
-1191.8%
Q1 24
-2616.7%
-2041.6%
Net Margin
ABSI
ABSI
DNTH
DNTH
Q4 25
-4548.0%
-22687.3%
Q3 25
-9284.1%
Q2 25
-5155.0%
Q1 25
-2234.6%
-2537.5%
Q4 24
-4358.3%
-2144.8%
Q3 24
-1610.7%
-1159.0%
Q2 24
-1948.8%
-945.1%
Q1 24
-2447.1%
-1573.0%
EPS (diluted)
ABSI
ABSI
DNTH
DNTH
Q4 25
$-0.19
$-1.53
Q3 25
$-0.97
Q2 25
$-0.24
Q1 25
$-0.21
$-0.82
Q4 24
$-0.26
$-0.76
Q3 24
$-0.24
$-0.74
Q2 24
$-0.22
$-0.51
Q1 24
$-0.22
$-0.54

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABSI
ABSI
DNTH
DNTH
Cash + ST InvestmentsLiquidity on hand
$144.3M
$404.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$189.4M
$493.4M
Total Assets
$216.3M
$530.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABSI
ABSI
DNTH
DNTH
Q4 25
$144.3M
$404.3M
Q3 25
$402.6M
Q2 25
$38.0M
Q1 25
$47.0M
$263.2M
Q4 24
$112.4M
$275.2M
Q3 24
$38.2M
$281.1M
Q2 24
$42.9M
$360.7M
Q1 24
$58.8M
$377.0M
Total Debt
ABSI
ABSI
DNTH
DNTH
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$4.0M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ABSI
ABSI
DNTH
DNTH
Q4 25
$189.4M
$493.4M
Q3 25
$546.5M
Q2 25
$173.4M
Q1 25
$198.8M
$328.6M
Q4 24
$179.1M
$352.5M
Q3 24
$201.3M
$337.9M
Q2 24
$221.5M
$358.2M
Q1 24
$240.1M
$372.7M
Total Assets
ABSI
ABSI
DNTH
DNTH
Q4 25
$216.3M
$530.9M
Q3 25
$577.4M
Q2 25
$209.9M
Q1 25
$232.4M
$348.6M
Q4 24
$213.6M
$374.0M
Q3 24
$235.2M
$354.2M
Q2 24
$255.5M
$369.0M
Q1 24
$274.9M
$382.5M
Debt / Equity
ABSI
ABSI
DNTH
DNTH
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.02×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABSI
ABSI
DNTH
DNTH
Operating Cash FlowLast quarter
$-29.2M
$-47.0M
Free Cash FlowOCF − Capex
$-29.3M
$-47.1M
FCF MarginFCF / Revenue
-4505.4%
-16591.9%
Capex IntensityCapex / Revenue
15.8%
48.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-85.2M
$-132.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABSI
ABSI
DNTH
DNTH
Q4 25
$-29.2M
$-47.0M
Q3 25
$-30.6M
Q2 25
$-16.9M
Q1 25
$-21.8M
$-27.6M
Q4 24
$-17.0M
$-27.4M
Q3 24
$-20.7M
$-21.3M
Q2 24
$-16.8M
$-14.5M
Q1 24
$-17.9M
$-14.9M
Free Cash Flow
ABSI
ABSI
DNTH
DNTH
Q4 25
$-29.3M
$-47.1M
Q3 25
$-30.6M
Q2 25
$-17.1M
Q1 25
$-21.9M
$-27.7M
Q4 24
$-17.0M
$-27.5M
Q3 24
$-20.8M
$-21.3M
Q2 24
$-17.2M
$-14.5M
Q1 24
$-15.0M
FCF Margin
ABSI
ABSI
DNTH
DNTH
Q4 25
-4505.4%
-16591.9%
Q3 25
-7717.2%
Q2 25
-2883.0%
Q1 25
-1854.5%
-2377.8%
Q4 24
-2554.4%
-2072.0%
Q3 24
-1221.6%
-980.3%
Q2 24
-1352.4%
-780.7%
Q1 24
-1713.2%
Capex Intensity
ABSI
ABSI
DNTH
DNTH
Q4 25
15.8%
48.6%
Q3 25
1.3%
Q2 25
37.6%
Q1 25
2.1%
2.1%
Q4 24
3.5%
2.3%
Q3 24
2.8%
1.2%
Q2 24
26.2%
0.9%
Q1 24
0.0%
3.7%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons